Kolexia
Khantalin Ilya
Chirurgie vasculaire
Hôpital Arnault Tzanck
Saint-Laurent-du-Var, France
37 Activités
198 Followers

Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Athérosclérose Anévrysme de l'aorte thoracique Acute Aortic Syndrome Anévrysme Syndrome coronarien aigu Maladies de l'aorte Hyperlipoprotéinémie de type II Hypercholestérolémie Rupture d'anévrysme

Industries

Boston Scientific
1 collaboration(s)
Dernière en 2023
CARDINAL HEALTH FRANCE 506 SAS
1 collaboration(s)
Dernière en 2020
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

COLLIPAR: Clinico-biological Collection of Subjects With Hyper Lipoprotein a in Reunion Island
Essai Clinique (CHU La Réunion)   29 août 2022
Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk.
Circulation. Genomic and precision medicine   08 février 2022
Large Extracellular Vesicle-Associated Rap1 Accumulates in Atherosclerotic Plaques, Correlates With Vascular Risks and Is Involved in Atherosclerosis.
Circulation research   16 juin 2020
Reduced Lipoprotein(a) Associated With the Apolipoprotein E2 Genotype Confers Cardiovascular Protection in Familial Hypercholesterolemia.
JACC. Basic to translational science   24 juin 2019
Development, synthesis, and Ga-Labeling of a Lipophilic complexing agent for atherosclerosis PET imaging.
European journal of medicinal chemistry   02 mai 2019
A rare location of the glomus tumor in the abdominal aorta.
Journal of vascular surgery cases and innovative techniques   30 avril 2019
Synthesis and Automated Labeling of FDarapladib, a Lp-PLA Ligand, as Potential PET Imaging Tool of Atherosclerosis.
ACS medicinal chemistry letters   04 avril 2019
Recurrent coronary syndromes in a patient with isolated very-high lipoprotein (a) and the prothrombin genetic variant rs1799963 (G20210A): a case report.
European heart journal. Case reports   25 février 2019
PCSK9: from biology to clinical applications.
Pathology   04 décembre 2018
PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.
Clinical science (London, England : 1979)   31 mai 2018